

Shanghai Market Outlook - 01 December 2021

Chinese share market finished session slight higher on Tuesday as investors reacted positively to improvement in Chinese manufacturing data and reports that the new coronavirus variant would be milder than initially dreaded.

The benchmark Shanghai Composite Index rose marginal 0.03%, or 1.19 points, to 3,563.89. The blue-chip CSI300 index was down 0.4%, or 19.39 points, to 4,832.03.

For the month, the CSI300 index went down 1.6%, while the Shanghai Composite Index edged up 0.5%.

Consumer staples dropped 2.3% and tourism shares shed 0.5%.

Information technology firms, semiconductors and defence stocks gained between 1% and 2.4%.

Services sector is more vulnerable to sporadic COVID-19 outbreaks as per analysts, clouding the outlook for the much-anticipated rebound in consumption in the months ahead.

The official manufacturing Purchasing Manager's Index (PMI) was at 50.1 in November, up from 49.2 in October, data from the National Bureau of Statistics.

The official non-manufacturing PMI in November eased to 52.3 from 52.4 in October, as the services sector took a hit from the fresh lockdown measures as China raced to contain the latest outbreak.

China's official October composite PMI, which includes both manufacturing and services activity, stood at 52.2, up from October's 50.8.

China's Ministry of Industry and Information Technology (MIIT) called for improved cross-border security management of big data till 2025, in a five-year plan published on Tuesday.

China's yuan strengthened against the U.S. dollar on Tuesday after firmer mid-point fixing, persistent corporate demand, and signs of liquidity tightness in the money markets.

Top Gainers

Company	Last Price	Change%
HCR Co. Ltd. A	¥43.45	14.40%
Bonree Data Technology Co. Ltd. A	¥62.02	11.35%
Jilin OIED Material Tech Co. Ltd. A	¥83.00	10.11%
Beijing Teamsun Technology Co. Ltd. A	¥6.99	10.08%
Sinomach Automobile Co. Ltd. A	¥7.43	10.07%

Top Losers

Company	Last Price	Change%
Qingdao Gaoce Technology Co. Ltd. A	¥78.20	-10.65%
CMST Development Co. Ltd. A	¥6.22	-9.99%
Sunway Co. Ltd. A	¥8.75	-8.95%
Henan Taloph Pharmaceutical Stock Co. Ltd.	¥8.61	-8.31%
Shanghai Laimu Electronics Co. Ltd.	¥16.57	-6.91%

Shanghai Market Outlook - 01 December 2021

Disclaimer and General Advice Instructions:

This document is provided by Laverne Securities Pty Ltd T/as Laverne Investing the Corporate Authorized Representative No. CAR No. 001269781 of Laverne Capital Pty Ltd AFSL 482937. The Research Analyst who prepared this report/article hereby certifies that the views expressed in this document accurately reflect the analyst's personal views about the Company and its financial products. The information provided in the Report/Article is provided by Morningstar. Laverne Fund is not a fund manager, however, the portfolio and the document is for general advice only, prepared by the Analysts and Research team for our clients.

This report/article have Different Assumptions, Views, Analytical Method of the analyst with no guarantee of reliability and accuracy of the content. The Research Analyst has not been, is not, and will not be receiving direct or indirect compensation for expressing the specific recommendations or views in this report/article. Laverne Securities has its own Research methodology, with regards to the rating and is confirmed by the team for long term Strategic rating of the concerned security as an Investment for Portfolios with High Growth High Risk Profile. Individual Stock is Speculative and of High Risk in nature and strongly

This Document is provided for the Advisors, their Clients, and Financial Professionals for information only and should not be considered an offer or solicitation of an offer to buy or sell a particular security or financial product or instrument.

The information or services provided in this report/article may not be suitable for you and we strongly recommend taking the advice of your Financial Planner or Investment advisors. Laverne Investing will not treat the recipients as its customer by virtue of their receiving the report/article and should seek the advice of their consultant, prior to making any investment decision considering this report/article